ToolGen KRX:199800KOSDAQ
툴젠 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days1
Articles tracked5since Sep 11
In Q2 2026, ToolGen reported revenue of ₩487m, up 241.6% year on year, and an operating loss of ₩6.9bn. ToolGen (툴젠) appeared in 1 Korean news article and 1 DART filing over the past seven days. Coverage peaked on Oct 29 with 1 article. It was most often mentioned alongside GC Genome.
Filing signals Insider buying 4 quarters of losses Screener
ToolGen quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩487m | +241.6% | −₩6.9bn | −₩6.8bn |
| Q1 2026 | ₩391m | +202.6% | −₩4.6bn | −₩4.4bn |
| Q4 2025 derived | ₩404m | +138.3% | −₩6.9bn | −₩22.5bn |
| Q3 2025 | ₩631m | +42.9% | −₩5.4bn | −₩5.4bn |
| Q2 2025 | ₩143m | -10.4% | −₩6.3bn | −₩4.4bn |
| Q1 2025 | ₩129m | +6.6% | −₩4.6bn | −₩4.4bn |
| Q4 2024 derived | ₩170m | -38.8% | −₩5.7bn | ₩22.5bn |
| Q3 2024 | ₩441m | -14.0% | −₩5.1bn | −₩5.2bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
ToolGen top stories 2 weeks, by number of outlets
- 1